FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048055596> ?p ?o ?g. }

• W2048055596 endingPage "255" @default.
• W2048055596 startingPage "249" @default.
• W2048055596 abstract "Tobramycin nebuliser solution (TNS) is indicated for maintenance therapy in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) infections. Adherence to recommended therapy in CF has always been a challenge and new generation nebulisers are increasingly used off label to reduce the time required for inhalation, potentially improving patient compliance.In this open-label, randomised, multi-centre, two-period crossover study, 27 CF patients with PA infection received TNS 300 mg/4 mL (TNS4) via the PARI eFlow(®) rapid or PARI LC Plus(®) nebuliser twice daily for 28 days in two study periods separated by a 4-week washout. The pharmacokinetic profile in plasma and sputum were determined after single and multiple dose administration on Day 1 and Day 28, respectively. Nebulisation times and general safety and tolerability profiles were evaluated throughout the study.Plasma tobramycin pharmacokinetic profiles were similar for the eFlow and LC Plus nebulisers both on Day 1 and Day 28. After multiple dose administration for 28 days, the eFlow/LC Plus ratio of geometric means for plasma C(max) and AUC(0-t), were 85.32 (90% CI, 61.24-118.86) and 87.44 (90% CI, 64.87-117.87), respectively. Despite the high variability, sputum tobramycin C(max) and AUC(0-t) for the eFlow on Day 28 tended to be higher than for the LC Plus (90% CI for the ratio, 86.11-226.45 and 81.81-236.71), respectively. Nebulisation times were significantly shorter for the eFlow with a median time for nebulisation of 5 min in comparison to 13 min for the LC Plus. Safety data confirmed a favourable safety profile for TNS4, with the majority of the findings being related to the underlying CF disease.Plasma and sputum pharmacokinetic data in CF patients with chronic PA infection support comparable pulmonary delivery and safety of TNS4 administered using different nebulisers, with a significantly shorter nebulisation time for the eFlow." @default.
• W2048055596 created "2016-06-24" @default.
• W2048055596 creator A5011256855 @default.
• W2048055596 creator A5011676406 @default.
• W2048055596 creator A5013070694 @default.
• W2048055596 creator A5023979944 @default.
• W2048055596 creator A5029140823 @default.
• W2048055596 creator A5030118395 @default.
• W2048055596 creator A5070982242 @default.
• W2048055596 date "2013-04-01" @default.
• W2048055596 modified "2023-09-27" @default.
• W2048055596 title "Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow® rapid and PARI LC Plus® nebulisers in cystic fibrosis patients" @default.
• W2048055596 cites W1971937804 @default.
• W2048055596 cites W1984893629 @default.
• W2048055596 cites W1990987230 @default.
• W2048055596 cites W1996215008 @default.
• W2048055596 cites W2030631267 @default.
• W2048055596 cites W2033434224 @default.
• W2048055596 cites W2064864100 @default.
• W2048055596 cites W2079326067 @default.
• W2048055596 cites W2085033676 @default.
• W2048055596 cites W2089995900 @default.
• W2048055596 cites W2099500833 @default.
• W2048055596 cites W2101219380 @default.
• W2048055596 cites W2107189796 @default.
• W2048055596 cites W2111364728 @default.
• W2048055596 cites W2120857717 @default.
• W2048055596 cites W2125078269 @default.
• W2048055596 cites W2142209182 @default.
• W2048055596 cites W2155069031 @default.
• W2048055596 cites W2162860932 @default.
• W2048055596 cites W2165433253 @default.
• W2048055596 cites W2170927479 @default.
• W2048055596 cites W2172285809 @default.
• W2048055596 cites W2317332612 @default.
• W2048055596 cites W29861392 @default.
• W2048055596 cites W2994597783 @default.
• W2048055596 doi "https://doi.org/10.1016/j.pupt.2012.12.002" @default.
• W2048055596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23232039" @default.
• W2048055596 hasPublicationYear "2013" @default.
• W2048055596 type Work @default.
• W2048055596 sameAs 2048055596 @default.
• W2048055596 citedByCount "18" @default.
• W2048055596 countsByYear W20480555962013 @default.
• W2048055596 countsByYear W20480555962014 @default.
• W2048055596 countsByYear W20480555962015 @default.
• W2048055596 countsByYear W20480555962016 @default.
• W2048055596 countsByYear W20480555962017 @default.
• W2048055596 countsByYear W20480555962018 @default.
• W2048055596 countsByYear W20480555962020 @default.
• W2048055596 countsByYear W20480555962021 @default.
• W2048055596 countsByYear W20480555962022 @default.
• W2048055596 crossrefType "journal-article" @default.
• W2048055596 hasAuthorship W2048055596A5011256855 @default.
• W2048055596 hasAuthorship W2048055596A5011676406 @default.
• W2048055596 hasAuthorship W2048055596A5013070694 @default.
• W2048055596 hasAuthorship W2048055596A5023979944 @default.
• W2048055596 hasAuthorship W2048055596A5029140823 @default.
• W2048055596 hasAuthorship W2048055596A5030118395 @default.
• W2048055596 hasAuthorship W2048055596A5070982242 @default.
• W2048055596 hasConcept C112705442 @default.
• W2048055596 hasConcept C126322002 @default.
• W2048055596 hasConcept C126894567 @default.
• W2048055596 hasConcept C141071460 @default.
• W2048055596 hasConcept C142724271 @default.
• W2048055596 hasConcept C185592680 @default.
• W2048055596 hasConcept C197934379 @default.
• W2048055596 hasConcept C204787440 @default.
• W2048055596 hasConcept C27081682 @default.
• W2048055596 hasConcept C2775832221 @default.
• W2048055596 hasConcept C2776301714 @default.
• W2048055596 hasConcept C2776938444 @default.
• W2048055596 hasConcept C2778375690 @default.
• W2048055596 hasConcept C2778974779 @default.
• W2048055596 hasConcept C2781069245 @default.
• W2048055596 hasConcept C42219234 @default.
• W2048055596 hasConcept C501593827 @default.
• W2048055596 hasConcept C55493867 @default.
• W2048055596 hasConcept C71924100 @default.
• W2048055596 hasConcept C87813604 @default.
• W2048055596 hasConcept C98274493 @default.
• W2048055596 hasConceptScore W2048055596C112705442 @default.
• W2048055596 hasConceptScore W2048055596C126322002 @default.
• W2048055596 hasConceptScore W2048055596C126894567 @default.
• W2048055596 hasConceptScore W2048055596C141071460 @default.
• W2048055596 hasConceptScore W2048055596C142724271 @default.
• W2048055596 hasConceptScore W2048055596C185592680 @default.
• W2048055596 hasConceptScore W2048055596C197934379 @default.
• W2048055596 hasConceptScore W2048055596C204787440 @default.
• W2048055596 hasConceptScore W2048055596C27081682 @default.
• W2048055596 hasConceptScore W2048055596C2775832221 @default.
• W2048055596 hasConceptScore W2048055596C2776301714 @default.
• W2048055596 hasConceptScore W2048055596C2776938444 @default.
• W2048055596 hasConceptScore W2048055596C2778375690 @default.
• W2048055596 hasConceptScore W2048055596C2778974779 @default.
• W2048055596 hasConceptScore W2048055596C2781069245 @default.
• W2048055596 hasConceptScore W2048055596C42219234 @default.
• W2048055596 hasConceptScore W2048055596C501593827 @default.

• next